AstraZeneca: to present progress in hematology
(CercleFinance.com) - AstraZeneca announces that 57 abstracts will be presented at the 66th Annual Meeting of the American Society of Hematology (ASH) in December 2024, covering 13 approved and potential treatments for hematological diseases such as chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and paroxysmal nocturnal hemoglobinuria (PNH).
Anas Younes, Senior Vice-President, Hematology R&D, points out that data from the AMPLIFY Phase III study will demonstrate Calquence's efficacy in CLL.
Christophe Hotermans, Senior Vice-President at Alexion, emphasises the transformative impact of Voydeya for patients with PNH.
Studies will also show the potential of AZD0486, a T-cell activator, and AZD0120, a CAR-T therapy, in lymphoma and MM.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Anas Younes, Senior Vice-President, Hematology R&D, points out that data from the AMPLIFY Phase III study will demonstrate Calquence's efficacy in CLL.
Christophe Hotermans, Senior Vice-President at Alexion, emphasises the transformative impact of Voydeya for patients with PNH.
Studies will also show the potential of AZD0486, a T-cell activator, and AZD0120, a CAR-T therapy, in lymphoma and MM.
Copyright (c) 2024 CercleFinance.com. All rights reserved.